Ustekinumab news

All news on Ustekinumab (also known as STELARA®): plants, production capacities, investments and involved companies.

15 July 2026

Johnson & Johnson Q2 2026 results and raises 2026 outlook

Quarterly sales topped $25.3B; adjusted net earnings and EPS rose, free cash flow improved, and full-year revenue guidance was raised above $100B for the first time.
31 October 2025

Johnson & Johnson Seeks FDA Approval for STELARA in Pediatric Ulcerative Colitis

sBLA submitted for STELARA to treat pediatric ulcerative colitis, backed by Phase 3 UNIFI Jr trial data, aiming to expand treatment options for children.

Who will be producing Ustekinumab in the future?

Find out with chemXplore Alpha

Learn more